NCT05194189

Clinical Efficacy of Megadose Vitamin C in Sepsis

Name: Clinical Trial NCT05194189
Creator: Zhujiang Hospital
Keywords: Sepsis,Septic Shock, Vitamin C, Phase 2, drug, clinical trial, China

Clinical Efficacy of Megadose Vitamin C in Sepsis (CEMVIS): A Multicenter, Randomized, Single-blind, Placebo-controlled Clinical Trial

Zhujiang Hospital·Phase 2·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Sepsis,Septic Shock
Drug/Device/Intervention: Vitamin C
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Zhujiang Hospital
Location: Dongguan,Foshan,Guanzhou,Yunfu,Zhongshan, China

Timeline & enrollment

Phase: Phase 2
Start date: Feb 08, 2022
End date: Jan 04, 2024
Enrollment: 152 participants

Primary outcome

28-day all-cause mortality

Summary

In this multicenter, randomized, single-blind, placebo-controlled clinical trial. Patients will be randomly assigned to receive Vitamin C or placebo for 4 days or until ICU discharge (whatever come first). The primary outcome is 28-day all-cause mortality.

ICD-10 classifications

Septic shockOther sepsisOther specified sepsisSepsis, unspecifiedSepsis due to other specified staphylococcus

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05194189
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05194189 through Pure Global AI's free database. This Phase 2 trial is sponsored by Zhujiang Hospital and is currently Recruiting. The study focuses on Sepsis,Septic Shock. Target enrollment is 152 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.